Literature DB >> 17868775

Colorectal adenocarcinoma involving the prostate: report of 9 cases.

Adeboye O Osunkoya1, George J Netto, Jonathan I Epstein.   

Abstract

We present 9 consult cases, the largest series to date, of colorectal adenocarcinoma involving the prostate. Mean age of patients at diagnosis was 61 years (range, 42-78 years). Six cases were initially diagnosed on needle biopsy and the others by transurethral resection. Three cases were diagnosed before biopsy of the colon, which led to the discovery of a primary colonic tumor. The mean interval between the detection of the primary colonic tumor and prostatic involvement in the other 6 cases was 30 months (range, 1-52 months). At diagnosis, the stages of colorectal carcinomas were pT1 (n=2), pT2 (n=2), pT3 (n=2), and pT4 (n=3). Two cases involved the prostate after the recurrence of rectal adenocarcinoma at the anastomotic site of the previous colonic resection. In most cases, the tumors were typical moderately differentiated with occasional poorly differentiated foci. Other histologic features included desmoplastic stromal reaction (100%, n=9), necrosis (77.8%, n=7), chronic inflammatory response (77.8%, n=7), cribriform pattern (66.7%, n=6), villous architecture (22.2%, n=2), mucin production (22.2%, n=2), signet-ring cells (11.1%, n=1), and perineural invasion (11.1%, n=1). Immunohistochemical stains were positive for beta-catenin in 6 of 6 cases, CDX2 in 6 of 6 cases, carcinoembryonic antigen in 7 of 7 cases, CK20 in 5 of 6 cases, high-molecular-weight cytokeratin in 5 of 6 cases, and alpha-methylacyl-CoA racemase in 3 of 6 cases. Stains were negative in all cases for prostate-specific antigen, P501S (prostein), and CK7. Six patients (66.7%) died of disease within an average of 34 months (range, 8-88 months) after diagnosis of prostatic involvement. There are critical therapeutic and prognostic implications for distinguishing between prostatic adenocarcinoma and colorectal carcinoma involving the prostate. Colorectal adenocarcinoma should be considered on prostate sampling when carcinoma exhibits either "dirty" necrosis, tall columnar epithelium with mucin production, mucin-positive signet-ring cells, villous architecture, or associated inflammation. Immunohistochemical stains for beta-catenin, CDX2, carcinoembryonic antigen, high-molecular-weight cytokeratin, prostate-specific antigen, P501S (prostein), CK20, and CK7 can be helpful in making a definitive diagnosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17868775     DOI: 10.1016/j.humpath.2007.04.021

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  5 in total

Review 1.  Signet-ring cell carcinoma of colorectum--current perspectives and molecular biology.

Authors:  Vinod Gopalan; Robert Anthony Smith; Yik-Hong Ho; Alfred King-Yin Lam
Journal:  Int J Colorectal Dis       Date:  2010-08-05       Impact factor: 2.571

2.  Primary enteric-type mucinous adenocarcinoma of the urethra in a patient with ulcerative colitis.

Authors:  Dimitrios Dimitroulis; Dimitrios Patsouras; Athanasios Katsargyris; Petros Charalampoudis; Ioannis Anastasiou; Gregory Kouraklis
Journal:  Int Surg       Date:  2014 Sep-Oct

Review 3.  Imaging of non-epithelial neoplasms of the prostate.

Authors:  Pankaj Nepal; Arpit Nagar; Sree Harsha Tirumani; Vijayanadh Ojili
Journal:  Abdom Radiol (NY)       Date:  2020-09-22

4.  Prostate carcinomas mimicking a digestive malignancy.

Authors:  Sorin Dema; Alis Liliana Carmen Dema; Sorina Tăban; Bianca Roxana Natarâş; Livius Cosmin Daminescu; Ciprian Constantin Duţă; Alin Adrian Cumpănaş; Tiberiu Răzvan Bardan
Journal:  Rom J Morphol Embryol       Date:  2020 Jul-Sep       Impact factor: 1.033

5.  Simultaneous robotic low anterior resection and prostatectomy for adenocarcinoma of rectum and prostate: initial case report.

Authors:  Myungchan Park; Seong Cheol Kim; Jae-Seung Chung; Sang Hyun Park; Seok San Park; Sung Jin Oh; Donghoon Lee; Koon Ho Rha; Cheol Kyu Oh
Journal:  Springerplus       Date:  2016-10-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.